<DOC>
	<DOCNO>NCT02104674</DOCNO>
	<brief_summary>This Phase III , randomize , double-blind , placebo-controlled , multicenter study assess efficacy safety lebrikizumab adult patient mild moderate asthma treat short-acting beta-agonist ( SABA ) therapy alone . Patients randomize 1:1:1 ratio receive either blind lebrikizumab placebo treatment subcutaneous ( SC ) injection ( every 4 week total 3 dos ) open-label treatment Singulair ( Montelukast ; 10 mg daily ) . Time study treatment last 12 week .</brief_summary>
	<brief_title>A Study Evaluating Efficacy Safety Lebrikizumab Adult Patients With Mild Moderate Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Montelukast</mesh_term>
	<criteria>Age 1875 year old study start Asthma diagnosis &gt; /= 12 month prior study start Bronchodilator response screen Prebronchodilator FEV1 60 % 85 % predict screen visit 2 3 No clinically significant lung disease confirm chest Xray compute tomography ( CT ) scan Stable symptomatic asthma screen period Use effective contraception , define protocol , 24 week last dose Maintenance corticosteroid therapy , define daily alternateday oral corticosteroid maintenance therapy within 3 month prior study start Treatment systemic inhale corticosteroid within 4 week prior study start screen period reason , include acute exacerbation event Treatment leukotriene receptor antagonist ( LTRA ) , longacting betaagonist ( LABA ) longacting muscarinic antagonist ( LAMA ) , zileuton , roflumilast , theophylline within 2 week prior study start Documented prior treatment failure Montelukast Treatment intraarticular corticosteroid within 4 week prior study start screen period anticipate need intra articular corticosteroid course study Any infection require hospital , IV IM antibiotic treatment respiratory infection within 4 week study start . Any infection require oral antibiotic treatment within 2 week study start , parasitic infection within 6 month study start Clinically significant abnormality find screen clinically significant medical disease uncontrolled despite treatment likely , opinion investigator , impact patient 's ability participate study , impact study assessment History interstitial lung disease , chronic obstructive pulmonary disease ( COPD ) , clinically significant lung disease asthma History alcohol drug abuse would impair risk patient 's full participation study , opinion investigator Current history smoking ( &gt; 10 packyears ) , unwillingness abstain smoking duration study Past and/or current use antiIL13 anti IL4/IL13 therapy , include lebrikizumab Use license investigational monoclonal antibody anti IL13 antiIL4/IL13 , include , limited , omalizumab , antiIL5 , anti IL17 , within 6 month 5 drug halflives prior Visit 1 ( whichever longer ) screen Use systemic immunomodulatory immunosuppressive therapy within 3 month 5 drug halflives prior study start screen Use investigational therapy within 4 week 5 drug halflives prior study start ( whichever longer ) screen Initiation change allergen immunotherapy within 3 month prior study start screen Receipt live attenuate vaccine within 4 week prior study start screen Pregnancy breast feed Body mass index &gt; 38 kg/m2 Body weight &lt; 40 kg History bronchial thermoplasty</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>